Dabrafenib for the treatment of melanoma.

Abstract excerpt

INTRODUCTION: Approximately 50% of patients with cutaneous melanoma have an activating mutation in BRAF kinase, leading to constitutive activation of the mitogen-activated protein kinase pathway and unregulated cell growth. Selective inhibitors of the mutated BRAF kinase produce response rates of approximately 50% with median progression-free survival of 6 - 7 months. BRAF-blocking therapies work rapidly, with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Brain Neoplasms
• Share to Imidazoles